The Boston-based digital pathology firm's updated US Food and Drug Administration clearance will help it to quickly validate its software with new hardware combinations.

Oncologists were one of the few provider groups to register support for the FDA rule, reflecting the challenge of assessing ...

The company also offers platform-agnostic next-generation sequencing tests and a suite of sample prep and thermal cycling instruments.

Premier Medical owner and CEO Kevin Murdock paid kickbacks for cancer genetic testing referrals, defrauding Georgia, Colorado, and South Carolina Medicaid, DOJ said.

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.

The agency said that the test is unnecessary for the screening of whole blood and blood components that are screened with nucleic acid tests and core antigen tests.

The company's next-generation sequencing-based test is used to aid the detection of cancers in patients with indeterminate ...

Last week, readers were most interested in a story about an extended collaboration between Personalis and Tempus to include colorectal cancer.

The partnership will initially focus on low-abundance biomarkers supporting translational research in Alzheimer's disease.

Breaking news on diagnostics business, policy, and funding. Real-time updates on clinical labs and the in vitro diagnostics market from 360Dx.

360Dx regularly updates this tracker to provide readers with accurate information on the regulatory status of these tests in the US, European, and Asian markets.

The Determine Antenatal Care Panel is used for the simultaneous detection of infectious diseases that threaten maternal and pediatric health.